ClinicalTrials.gg
CompletedNCT03746522Updated Dec 1, 2023Results posted

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

A Phase 3 interventional study of Setmelanotide and Placebo in Bardet Biedl Syndrome (BBS) and Alström Syndrome (AS), sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 12 sites in 6 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2023-12-01.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing setmelanotide in Obesity — 1 open to participants now, 2 under way, none of them phase 3. setmelanotide · Obesity.

Enrollment
7th of 16
52 · median 34
Started
2018
with 2 others
Phase 3
6 of 16
none open now
Registered
10th of 16
by date
Lead sponsor
15 of 16
Rhythm Pharmaceuticals, Inc.

Among the 16 studies testing setmelanotide in Obesity, this one is the 7th largest by enrollment, is one of 3 that started in 2018, is one of 6 in phase 3, and was the 10th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

1 of the 16 studies testing setmelanotide in Obesity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About setmelanotide

setmelanotide: first FDA approval 2020 (IMCIVREE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing setmelanotide in Obesity, or all of them as a file.
02

Study summary

This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type 4 (MC4R) agonist, for the treatment of obesity and hyperphagia in participants with Bardet Biedl syndrome (BBS) or Alström syndrome (AS). The study's primary efficacy endpoint is to evaluate the proportion of participants (≥ 12 years of age at baseline) who lose ≥ 10% of their baseline body weight following approximately (\~) 52 weeks of treatment with setmelanotide compared to a historical control rate.

Read the detailed description

Eligible participants will enter a 14-week, randomized, double-blind, placebo-controlled treatment period (Period 1) that will be followed by a 38-week open-label treatment period (Period 2) in which all participants will receive setmelanotide. Following Period 2, participants will continue receiving open-label setmelanotide for 14 weeks (Period 3), after which they could enroll into a separate treatment extension study.

03

Conditions studied

  • Bardet Biedl Syndrome (BBS)
  • Alström Syndrome (AS)

Browse trials for

Keywords

  • MC4R Pathway
  • Obesity
  • BBS
  • AS
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. BBS clinical diagnosis or AS diagnosis
  2. Greater than or equal to (≥) 6 years of age.
  3. Obese, defined as ≥30 kilograms/meters\^2 for participants ≥16 years of age or weight >97th percentile for age and sex on growth chart assessment for participants 6 to 15 years of age.
  4. Study participant and/or parent or guardian is able to communicate well with the Investigator, to understand and comply with the requirements of the study, and is able to understand and sign the written /assent.
  5. Female participants of must be confirmed non-pregnant and agree to use as outlined in the protocol. Female participants of non-childbearing potential, defined as: surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation), for at least 12 months (and confirmed with a screening follicle stimulating hormone (FSH) level in the post-menopausal lab range), or failure to have progressed to Tanner Stage V and/or failure to have achieved menarche, do not require contraception during the study.
  6. Male participants with female partners of childbearing potential must agree to use a double barrier method contraception if they become sexually active during the study or within 90 days following their participation in the study. Male participants must also not donate sperm during and for 90 days following their participation in the study.

Exclusion criteria

Exclusion Criteria:

  1. Recent intensive (within 2 months) diet and/or exercise regimen with or without the use of weight loss agents (including herbal medications) that has resulted in >2% weight loss. These participants may be reconsidered approximately 1 month after cessation of such intensive regimens.
  2. Current or prior (within prior 2 months) use of any medication, including those approved to treat obesity, that could impact the efficacy results of this study (e.g., orlistat, lorcaserin, phentermine-topiramate, naltrexone-bupropion, liraglutide). Participants on a stable dose and regimen (for at least 2 months) of medication to treat attention deficit hyperactivity disorder (ADHD) may be enrolled in the study as long as they agree to remain on the same dose and regimen during the study.
  3. Prior gastric bypass surgery resulting in >10% weight loss durably maintained from the baseline pre-operative weight with no evidence of weight regain. Specifically, participants may be considered if surgery was not successful, resulted in \<10% weight loss compared to pre-operative baseline weight, or there is clear evidence of weight regain after an initial response to bariatric surgery. All participants with a history of bariatric surgery must be discussed with, and receive approval from, the Sponsor prior to enrollment.
  4. Diagnosis of schizophrenia, bipolar disorder, personality disorder or other fifth edition (DSM-V) disorders that the Investigator believes will interfere significantly with study compliance. Neurocognitive disorders affecting ability to consent will not be disqualifying as long as an appropriate guardian able to give consent has been appointed.
  5. In participants with no significant neurocognitive deficits:

    • A Patient Health Questionnaire-9 (PHQ-9) score of ≥15 and/or
    • Any suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS), any lifetime history of a suicide attempt, or any suicidal behavior in the last month.
  6. Current, pulmonary, cardiac, or oncologic disease considered severe enough to interfere with the study and/or confound the results. Any participant with a potentially clinically significant disease should be reviewed with the Sponsor to determine eligibility.
  7. History of significant liver disease or liver injury, or a current liver assessment due to abnormal liver tests (as indicated by abnormal liver function tests, [ALT], aspartate transaminase [AST], alkaline phosphatase, or serum >1.5x the [ULN] for any of these tests) for an etiology other than non-alcoholic fatty liver disease (NAFLD). Thus, any underlying etiology besides NAFLD, including diagnosed non-alcoholic steatohepatitis (NASH), other causes of hepatitis, or history of hepatic cirrhosis is exclusionary, but the presence of NAFLD is not exclusionary.
  8. Moderate to severe renal dysfunction defined as \<30 mL/min.
  9. History or close family history (parents or siblings) of skin cancer or melanoma (excluding non-invasive basal or squamous cell lesion), or participant history of ocular-cutaneous albinism.
  10. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion).
  11. Participant is, in the opinion of the Study Investigator, not suitable to participate in the study.
  12. Participation in any clinical study with an drug/device within 3 months prior to the first day of dosing.
  13. Significant to study drug.
  14. Inability to comply with once daily (QD) injection regimen.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Setmelanotide (Double-Blind)

    Participants received once daily SC injection of setmelanotide for 14 weeks in a double-blind placebo-controlled treatment period (Period 1). Participants ≥16 years of age started on setmelanotide 2.0 mg with dose escalation to 3.0 mg. Participants \<16 years of age started on setmelanotide 1.0 mg with dose escalation to 3.0 mg.

    Drug: Setmelanotide

  • Placebo comparator
    Placebo (Double-Blind)

    Participants received once daily SC injection of placebo (matching setmelanotide) for 14 weeks in a double-blind placebo-controlled treatment period (Period 1).

    Drug: Placebo

  • Experimental
    Setmelanotide (Open-label)

    After the initial 14-week double-blind treatment period, all participants immediately transitioned to open-label setmelanotide once daily SC injection for 38 weeks (Period 2) and then continued to receive setmelanotide in the 14-week open-label treatment period (Period 3).

    Drug: Setmelanotide

Interventions

  • SC injection of setmelanotide

    Also known as: SET, RM-493

  • DrugPlacebo

    SC injection of placebo

06

What researchers measure

Primary outcomes

  1. Percentage of Participants (≥12 Years of Age at Baseline) Who Reached ≥10% Weight Loss Threshold After 1 Year (Period 2): Pivotal Cohort

    The percentage of participants (≥12 years of age at baseline) who achieved a ≥10% reduction from baseline in body weight at Period 2 or after 52 weeks of treatment with setmelanotide were analyzed. There was a 14-week placebo-controlled period at the beginning of the trial. After completion of the placebo-controlled period, all participants from the placebo group switched to setmelanotide treatment. The placebo group was integrated into the 52-week analysis so that the participants who received placebo, had 52 weeks of setmelanotide treatment after the first dose of "active" treatment. Placebo participants were also included in this analysis.

    Time frame: 52 weeks

Secondary outcomes

  1. Mean Percent Change From Baseline in Body Weight (≥12 Years of Age) at Week 52 (Period 2): Pivotal Cohort

    The mean percent change from baseline in body weight at 52 weeks was analyzed. There was a 14-week placebo-controlled period at the beginning of the trial. After completion of the placebo-controlled period, all participants from the placebo group switched to setmelanotide treatment. The placebo group was integrated into the 52-week analysis so that the participants who received placebo, had 52 weeks of setmelanotide treatment after the first dose of "active" treatment. Placebo participants were also included in this analysis.

    Time frame: Baseline, Week 52

  2. Mean Percent Change From Baseline in the Weekly Average of the Daily Hunger Score (≥12 Years of Age) at Week 52 (Period 2): Pivotal Cohort

    Mean percent change in hunger scores for participants ≥12 years of age with leptin receptor (LEPR) deficiency obesity in treatment with setmelanotide was evaluated. Hunger score ranged from 0= "not hungry at all" to 10= "hungriest possible" on Likert-type scale. On Daily Hunger Questionnaire, each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged on weekly basis. Weekly average hunger score of daily worst (most) hunger score in 24 hours is the hunger score used to assess this study endpoint. There was a 14-week placebo-controlled period at the beginning of the trial. After completion of the placebo-controlled period, all participants from the placebo group switched to setmelanotide treatment. Placebo group was integrated into the 52-week analysis so that participants who received placebo, had 52 weeks of setmelanotide treatment after the first dose of "active" treatment. Placebo participants were also included in this analysis.

    Time frame: Baseline, Week 52

  3. Number of Participants (≥12 Years of Age With no Cognitive Impairment) Who Achieved a ≥ 25% Improvement in the Weekly Average of the Daily Hunger Score From Baseline at Week 52 (Period 2): Pivotal Cohort

    Number of participants (≥12 years of age with no cognitive impairment) achieving ≥25% improvement from baseline in hunger score at Week 52 was assessed. Hunger score ranged from 0= "not hungry at all" to 10= "hungriest possible" on Likert-type scale. On Daily Hunger Questionnaire, each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged on weekly basis. Weekly average hunger score of daily worst (most) hunger score in 24 hours is the hunger score used to assess this study endpoint. There was a 14-week placebo-controlled period at the beginning of the trial. After completion of placebo-controlled period, all participants from placebo group switched to setmelanotide treatment. Placebo group was integrated into the 52-week analysis so that participants who received placebo, had 52 weeks of setmelanotide treatment after the first dose of "active" treatment. Placebo participants were also included in this analysis.

    Time frame: Baseline, Week 52

07

Results

Posted Dec 1, 2023

Participant flow

Participants were enrolled in pivotal cohort (38 participants) or supplemental cohort (14 participants) and received setmelanotide/placebo for the 14-week double-blind period (Period 1) followed by setmelanotide in the open-label period (Period 2 and 3).

Period 1: Double-Blind (14 Weeks)
Participant flow — Period 1: Double-Blind (14 Weeks)
MilestoneSetmelanotide (Double-Blind)Placebo (Double-Blind)Setmelanotide (Open-label)
Started27250
Completed27230
Not completed020
Withdrew: Adverse event010
Withdrew: Withdrawal by subject010
Period 2: Open-Label (38 Weeks)
Participant flow — Period 2: Open-Label (38 Weeks)
MilestoneSetmelanotide (Double-Blind)Placebo (Double-Blind)Setmelanotide (Open-label)
Started0050
Completed0041
Not completed009
Withdrew: Withdrawal by subject003
Withdrew: Adverse event004
Withdrew: Other than specified002
Period 3: Open-Label (14 Weeks)
Participant flow — Period 3: Open-Label (14 Weeks)
MilestoneSetmelanotide (Double-Blind)Placebo (Double-Blind)Setmelanotide (Open-label)
Started0041
Completed0041
Not completed000

Outcome measures

PrimaryPercentage of Participants (≥12 Years of Age at Baseline) Who Reached ≥10% Weight Loss Threshold After 1 Year (Period 2): Pivotal Cohort

The percentage of participants (≥12 years of age at baseline) who achieved a ≥10% reduction from baseline in body weight at Period 2 or after 52 weeks of treatment with setmelanotide were analyzed. There was a 14-week placebo-controlled period at the beginning of the trial. After completion of the placebo-controlled period, all participants from the placebo group switched to setmelanotide treatment. The placebo group was integrated into the 52-week analysis so that the participants who received placebo, had 52 weeks of setmelanotide treatment after the first dose of "active" treatment. Placebo participants were also included in this analysis.

Time frame:
52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants (≥12 Years of Age at Baseline) Who Reached ≥10% Weight Loss Threshold After 1 Year (Period 2): Pivotal Cohort
percentage of participantsPivotal Cohort
Percentage of Participants (≥12 Years of Age at Baseline) Who Reached ≥10% Weight Loss Threshold After 1 Year (Period 2): Pivotal Cohort32.3 (16.7 to 51.4)
Statistical analysis
  • Pivotal Cohort · Rubin's Rule · p = 0.0006 (P-value was one-sided and compared with alpha = 0.025.)
SecondaryMean Percent Change From Baseline in Body Weight (≥12 Years of Age) at Week 52 (Period 2): Pivotal Cohort

The mean percent change from baseline in body weight at 52 weeks was analyzed. There was a 14-week placebo-controlled period at the beginning of the trial. After completion of the placebo-controlled period, all participants from the placebo group switched to setmelanotide treatment. The placebo group was integrated into the 52-week analysis so that the participants who received placebo, had 52 weeks of setmelanotide treatment after the first dose of "active" treatment. Placebo participants were also included in this analysis.

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Mean Percent Change From Baseline in Body Weight (≥12 Years of Age) at Week 52 (Period 2): Pivotal Cohort
percent changePivotal Cohort
Mean Percent Change From Baseline in Body Weight (≥12 Years of Age) at Week 52 (Period 2): Pivotal Cohort-5.21 ± 7.895
Statistical analysis
  • Pivotal Cohort · Rubin's Rule · p = 0.0005 (p-value was one-sided and compared with alpha = 0.025)
SecondaryMean Percent Change From Baseline in the Weekly Average of the Daily Hunger Score (≥12 Years of Age) at Week 52 (Period 2): Pivotal Cohort

Mean percent change in hunger scores for participants ≥12 years of age with leptin receptor (LEPR) deficiency obesity in treatment with setmelanotide was evaluated. Hunger score ranged from 0= "not hungry at all" to 10= "hungriest possible" on Likert-type scale. On Daily Hunger Questionnaire, each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged on weekly basis. Weekly average hunger score of daily worst (most) hunger score in 24 hours is the hunger score used to assess this study endpoint. There was a 14-week placebo-controlled period at the beginning of the trial. After completion of the placebo-controlled period, all participants from the placebo group switched to setmelanotide treatment. Placebo group was integrated into the 52-week analysis so that participants who received placebo, had 52 weeks of setmelanotide treatment after the first dose of "active" treatment. Placebo participants were also included in this analysis.

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Mean Percent Change From Baseline in the Weekly Average of the Daily Hunger Score (≥12 Years of Age) at Week 52 (Period 2): Pivotal Cohort
percent changePivotal Cohort
Mean Percent Change From Baseline in the Weekly Average of the Daily Hunger Score (≥12 Years of Age) at Week 52 (Period 2): Pivotal Cohort-30.91 ± 24.733
Statistical analysis
  • Pivotal Cohort · Rubin's Rule · p = <0.0001 (p-value was one-sided and compared with alpha=0.025.)
SecondaryNumber of Participants (≥12 Years of Age With no Cognitive Impairment) Who Achieved a ≥ 25% Improvement in the Weekly Average of the Daily Hunger Score From Baseline at Week 52 (Period 2): Pivotal Cohort

Number of participants (≥12 years of age with no cognitive impairment) achieving ≥25% improvement from baseline in hunger score at Week 52 was assessed. Hunger score ranged from 0= "not hungry at all" to 10= "hungriest possible" on Likert-type scale. On Daily Hunger Questionnaire, each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged on weekly basis. Weekly average hunger score of daily worst (most) hunger score in 24 hours is the hunger score used to assess this study endpoint. There was a 14-week placebo-controlled period at the beginning of the trial. After completion of placebo-controlled period, all participants from placebo group switched to setmelanotide treatment. Placebo group was integrated into the 52-week analysis so that participants who received placebo, had 52 weeks of setmelanotide treatment after the first dose of "active" treatment. Placebo participants were also included in this analysis.

Time frame:
Baseline, Week 52
Reported as:
Count of participants · Participants
Number of Participants (≥12 Years of Age With no Cognitive Impairment) Who Achieved a ≥ 25% Improvement in the Weekly Average of the Daily Hunger Score From Baseline at Week 52 (Period 2): Pivotal Cohort
ParticipantsPivotal Cohort
Number of Participants (≥12 Years of Age With no Cognitive Impairment) Who Achieved a ≥ 25% Improvement in the Weekly Average of the Daily Hunger Score From Baseline at Week 52 (Period 2): Pivotal Cohort10
Statistical analysis
  • Pivotal Cohort · Rubin's Rule · p = <0.0001 (p-value was one-sided and compared with alpha = 0.025.)

Adverse events

Collected over Double-blind: From first dose up to Week 14 Open-label: From Week 14 up to Week 66. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Setmelanotide (Double-Blind Period)0/27 (0%)1/27 (3.7%)26/27 (96.3%)
Placebo (Double-Blind Period)0/25 (0%)2/25 (8%)24/25 (96%)
Setmelanotide (Open-label)0/50 (0%)0/50 (0%)45/50 (90%)
Most frequent serious events
Most frequent serious events
EventSetmelanotide (Double-Blind Period)Placebo (Double-Blind Period)Setmelanotide (Open-label)
BlindnessEye disorders0/271/250/50
Anaphylactic reactionImmune system disorders0/271/250/50
AnaemiaBlood and lymphatic system disorders1/270/250/50
Suicidal ideationPsychiatric disorders0/270/250/50
Most frequent other events
Showing 10 of 30
Most frequent other events
EventSetmelanotide (Double-Blind Period)Placebo (Double-Blind Period)Setmelanotide (Open-label)
Skin hyperpigmentationSkin and subcutaneous tissue disorders17/270/2519/50
Injection site erythemaGeneral disorders12/2711/254/50
Injection site pruritusGeneral disorders8/279/254/50
Injection site bruisingGeneral disorders6/279/253/50
Injection site painGeneral disorders3/278/255/50
NauseaGastrointestinal disorders7/276/258/50
VomitingGastrointestinal disorders7/270/258/50
HeadacheNervous system disorders1/276/257/50
Injection site indurationGeneral disorders6/274/255/50
High density lipoprotein decreasedInvestigations4/270/250/50

Baseline characteristics

Safety Analysis Set defined as participants who received at least 1 dose of study drug (placebo or setmelanotide).

Age, Continuous
Age, Continuous(years)SetmelanotidePlaceboTotal
Mean18.3 ± 9.9520.7 ± 12.0519.5 ± 10.96
Sex: Female, Male
Sex: Female, Male(Participants)SetmelanotidePlaceboTotal
Female131831
Male14721
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SetmelanotidePlaceboTotal
Hispanic or Latino101
Not Hispanic or Latino222244
Unknown or Not Reported437
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SetmelanotidePlaceboTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American224
White172138
More than one race000
Unknown or Not Reported718
Region of Enrollment
Region of Enrollment(Participants)SetmelanotidePlaceboTotal
Canada437
United States161733
United Kingdom022
France415
Spain325
08

Study locations

12 sites
  • Wr-McCr, Llc
    San Diego, California 92108, United States
  • UMMS Baystate Health; BAYSTATE MEDICAL CENTER; Baystate Children's Specialty Center
    Springfield, Massachusetts 01199, United States
  • Columbia University Center
    New York, New York 10032, United States
  • M3 Wake Research
    Raleigh, North Carolina 27612, United States
  • University of Tennessee Health Science Center
    Memphis, Tennessee 38103, United States
  • Marshfield Clinic Research Foundation
    Marshfield, Wisconsin 54449, United States
  • Alberta Health Services
    Edmonton, Alberta T6G 2E1, Canada
  • Sorbonne University, Hôpital de la Pitié-Salpêtrière
    Paris, 75013, France
  • Centre Hospitalier Universitaire de Strasbourg
    Strasbourg, 67091, France
  • UPR Medical Sciences Campus
    Rio Piedras, 00935, Puerto Rico
  • Universidad Autónoma de Madrid University Hospital Niño
    Madrid, 28009, Spain
  • St. Thomas Hospital
    London, SE1 7EH, United Kingdom
09

References and documents

Publications

  • Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GA, Poitou C, Yanovski JA, Mittleman RS, Yuan G, Forsythe E, Clement K, Argente J. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstrom syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol. 2022 Dec;10(12):859-868. doi: 10.1016/S2213-8587(22)00277-7. Epub 2022 Nov 7. Erratum In: Lancet Diabetes Endocrinol. 2023 Feb;11(2):e2. doi: 10.1016/S2213-8587(22)00360-6. PubMed 36356613 ↗
  • Haws RM, Gordon G, Han JC, Yanovski JA, Yuan G, Stewart MW. The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alstrom syndrome: Phase 3 trial design. Contemp Clin Trials Commun. 2021 May 3;22:100780. doi: 10.1016/j.conctc.2021.100780. eCollection 2021 Jun. PubMed 34013094 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Nov 2020, 23 months.

Results were first posted in Dec 2023, 3 years after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 23 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2018
First posted
Nov 19, 2018
StartActual
Nov 23, 2018
Primary completionActual
Nov 16, 2020
CompletionActual
Mar 8, 2021
Results first posted
Dec 1, 2023
Last update
Dec 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03746522
Responsible party
Sponsor
First posted
Nov 19, 2018
Start date
Nov 23, 2018
Primary completion
Nov 16, 2020
Completion
Mar 8, 2021
Results posted
Dec 1, 2023
Last update
Dec 1, 2023

Study contacts

David Meeker, MD
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion